SOURCE: Avita Medical

Avita Medical

May 05, 2016 20:36 ET

Research Confirms That ReCell® Reduces Long-Term Scarring and Itching Outcomes in Pediatric Burns Treatment

UK Study Results Presented at American Burn Association (ABA) Annual Meeting

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - May 5, 2016) - Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY) -- The ReCell® Autologous Cell Harvesting Device effectively reduces the occurrence of long-term scarring and itching symptoms associated with pediatric burn treatment, compared to various treatment modalities, according to results from a UK study presented at a major burns conference this week.

Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, reported key findings from the retrospective analysis presented this week at the American Burn Association (ABA) 48th Annual Meeting, being held May 3-6, 2016 in Las Vegas, NV.

In one of the first studies to explore long-term outcomes, the Pinderfields Hospital Regional Burns Unit, in Wakefield, United Kingdom, evaluated long-term outcomes in 100 pediatric patients with partial-thickness scalds. The patients, followed for three to four years, were treated with five different treatment modalities: ReCell® with conventional dressings, ReCell® with biological dressings, biological dressings, conventional dressings, and split-thickness skin grafting.

Results, presented by Dr Elliott Cochrane (Abstract #167), showed that ReCell® in combination with biological dressings was the most effective modality in terms of scar outcomes. Of the patients receiving split-thickness skin grafts, an 80% incidence of scarring was reported. This was reduced to 50% in patients who were treated with biological dressings alone. The incidence of scarring was just 25% for those receiving ReCell® with conventional dressings, and the lowest incidence, 22%, was observed for those treated with ReCell® combined with biological dressings. Patients complained of a higher level of itchiness (18%) with biological dressings (without ReCell), compared with 11% for ReCell® with biological dressings and 0% for ReCell® with conventional dressings. The researchers concluded that the treatment route combining biological dressings and Regenerative Epithelial Suspension™ (RES™) generated by ReCell® is the optimal wound healing environment and provides reduced patient discomfort as the wound re-epithelializes.

"These results confirm previously published work of Wood et al (2012) and what burns surgeons routinely using ReCell already know: that ReCell® can outperform alternative treatment options when considering key, practical clinical risks that patients commonly suffer from when undergoing burn treatment," said Avita CEO Adam Kelliher. "Scarring and itching are constant issues for our patient group, and we should always consider that about half of burns in Europe happen to children, who will have to endure these outcomes for life. Proving long-term benefit is of real significance."


ReCell® is Avita Medical's unique proprietary technology that enables a clinician to rapidly create, at point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES™) using a small sample of the patient's skin. RES™ is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES™ has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin.

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE‐marked for Europe, TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. A pivotal U.S. trial is underway, with patient enrollment completion anticipated by the end of 2015. To learn more, visit

Contact Information